HMDC.F Stock Overview
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
HUTCHMED (China) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£3.82 |
| 52 Week High | UK£3.95 |
| 52 Week Low | UK£2.05 |
| Beta | 0.65 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 5.97% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 82.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| HMDC.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.08% | 1.2% |
| 1Y | 6.0% | 13.2% | 24.9% |
Return vs Industry: HMDC.F underperformed the US Pharmaceuticals industry which returned 16.8% over the past year.
Return vs Market: HMDC.F underperformed the US Market which returned 16.6% over the past year.
Price Volatility
| HMDC.F volatility | |
|---|---|
| HMDC.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HMDC.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HMDC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,990 | Wei-Guo Su | www.hutch-med.com |
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3’-kinase delta).
HUTCHMED (China) Limited Fundamentals Summary
| HMDC.F fundamental statistics | |
|---|---|
| Market cap | US$2.45b |
| Earnings (TTM) | -US$29.42m |
| Revenue (TTM) | US$757.24m |
3.2x
P/S Ratio-83.3x
P/E RatioIs HMDC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HMDC.F income statement (TTM) | |
|---|---|
| Revenue | US$757.24m |
| Cost of Revenue | US$731.89m |
| Gross Profit | US$25.34m |
| Other Expenses | US$54.77m |
| Earnings | -US$29.42m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Feb 28, 2024
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 3.35% |
| Net Profit Margin | -3.89% |
| Debt/Equity Ratio | 5.0% |
How did HMDC.F perform over the long term?
See historical performance and comparison